NOVARTIS

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public, Private

Established: 1996-01-01

Employees: 76K

Market Cap: $242.6B

Website: https://www.novartis.com/our-science/novartis-institutes-biomedical-research

Clinical Trials

A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study

Phase 3

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: Ranibizumab
Procedure: Laser
Procedure: Sham laser
Drug: Sham to ranibizumab

First Posted Date: 2008-06-02

Last Posted Date: 2013-04-01

Lead Sponsor: Novartis

Target Recruit Count: 345

Registration Number: NCT00687804

Locations: 🇨🇭
Novartis Investigational Site, Zurich, Switzerland
🇬🇧
Novartis Investigative Site, Upton, United Kingdom

Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Phase 3

Completed

Conditions: Cryopyrin-Associated Periodic Syndromes
Muckle Wells Syndrome
Familial Cold Autoinflammatory Syndrome
Neonatal Onset Multisystem Inflammatory Disease

Interventions: Drug: Canakinumab (ACZ885)

First Posted Date: 2008-05-28

Last Posted Date: 2016-11-04

Lead Sponsor: Novartis

Target Recruit Count: 166

Registration Number: NCT00685373

Locations: 🇺🇸
Little Rock Allergy and Asthma Clinic, Little Rock, Arkansas, United States
🇺🇸
UCSF School of Medicine, San Francisco, California, United States
🇪🇸
Novartis Investigative Site, Vigo, Spain

and more 5 locations

Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: COPD

Interventions: Drug: Indacaterol
Drug: Placebo

First Posted Date: 2008-05-15

Last Posted Date: 2011-08-22

Lead Sponsor: Novartis

Target Recruit Count: 415

Registration Number: NCT00677807

Locations: 🇹🇷
Novartis Investigative Site, Kartal/Istanbul, Turkey
🇺🇸
Novartis Investigative SIte, Fullerton, California, United States
🇹🇷
Novartis Investigator Site, Yenisehir/Izmir, Turkey

and more 2 locations

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of PTH134 at Increasing Doses in Healthy Postmenopausal Subjects

Phase 1

Completed

Conditions: Postmenopausal Osteoporosis

Interventions: Drug: PTH134

First Posted Date: 2008-05-13

Last Posted Date: 2008-12-11

Lead Sponsor: Novartis

Target Recruit Count: 32

Registration Number: NCT00676312

Locations: 🇨🇭
Novartis Investigative site, Basel, Switzerland

Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy

Phase 4

Completed

Conditions: Polypoidal Choroidal Vasculopathy

Interventions: Drug: Verteporfin Photodynamic Therapy
Drug: Ranibizumab

First Posted Date: 2008-05-07

Last Posted Date: 2011-04-19

Lead Sponsor: Novartis

Target Recruit Count: 61

Registration Number: NCT00674323

Locations: 🇹🇭
Novartis Investigative Site, Bangkok, Thailand

Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload

Phase 4

Completed

Conditions: Hemoglobinopathies
Myelodysplastic Syndromes
Other Inherited or Acquired Anaemia
MPD Syndrome
Diamond-Blackfan Anemia
Other Rare Anaemias
Transfusional Iron Overload

Interventions: Drug: deferasirox

First Posted Date: 2008-05-07

Last Posted Date: 2017-02-23

Lead Sponsor: Novartis

Target Recruit Count: 118

Registration Number: NCT00673608

Locations: 🇦🇺
Novarts Investigative Site, Sydney, Australia

An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis

Phase 2

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Fingolimod

First Posted Date: 2008-05-01

Last Posted Date: 2013-09-04

Lead Sponsor: Novartis

Target Recruit Count: 143

Registration Number: NCT00670449

Locations: 🇯🇵
Novartis Investigative Site, Wakayama, Japan

Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Indacaterol
Drug: Salmeterol/fluticasone (50/500 μg)
Drug: Salbutamol (200 µg)
Drug: Placebo to Indacaterol
Drug: Placebo to Salmeterol/fluticasone
Drug: Placebo to salbutamol

First Posted Date: 2008-04-30

Last Posted Date: 2011-09-12

Lead Sponsor: Novartis

Target Recruit Count: 89

Registration Number: NCT00669617

Locations: 🇭🇺
Novartis Investigative site, Deszk, Hungary
🇭🇺
Novartis Investigative Site, Nyiregyhaza, Hungary
🇩🇪
Novartis Investigator Site, Potsdam, Germany

A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension

Phase 3

Completed

Conditions: Essential Hypertension

Interventions: Drug: Aliskiren
Drug: Amlodipine
Drug: Hydrochlorothiazide

First Posted Date: 2008-04-28

Last Posted Date: 2021-06-07

Lead Sponsor: Novartis

Target Recruit Count: 564

Registration Number: NCT00667719

Locations: 🇹🇷
Investigative Site, Turkey, Turkey

The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: valsartan and amlodipine

First Posted Date: 2008-04-25

Last Posted Date: 2016-10-27

Lead Sponsor: Novartis

Target Recruit Count: 728

Registration Number: NCT00666536

Locations: 🇺🇸
Egan Healthcare, Metairie, Louisiana, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy